US pharma giant Merck & Co (NYSE: MRK) has opted to pull the plug on two mid-stage trials of Alzheimer’s disease candidate MK-1942, due to safety worries.
The small molecule has been designed to promote the release of a certain chemical in the brain, glutamate, which scientists at the company believe could help treat a number of conditions.
As well as Alzheimer’s, Merck has been testing the candidate for people with difficult-to-treat major depressive disorder (MDD), who are on a stable course of antidepressant therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze